Compare Campbell Soup Co. (CPB) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Medpace Holdings Inc — how do they compare? Campbell Soup Co. trades at $19.2 (market cap $5.78B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 2.9× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays a 5.16% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and Medpace Holdings Inc for 14 Days on average.
| CPB | MEDP | |
|---|---|---|
Market Cap | $5.78B | $16.82B |
Volume | 11,705,427 | 223,093 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $630.19 |
52-Week Low | $18.90 | $393.42 |
Typical Hold Time | 98 Days | 14 Days |
Enterprise Value | $12.83B | $16.44B |
Dividend Yield | 5.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $19.12, up 1.16% on the day, with a bearish technical outlook and mixed analyst sentiment. The company reported a Q4 2026 earnings miss but beat expectations in Q1 and Q2 2026. Recent developments include a 36% dividend cut, a $500 million cost savings program, and workforce reductions. Valuation metrics show a P/E of 14.79 and P/S of 0.6, suggesting potential undervaluation amid operational challenges.
The outlook remains cautious due to margin pressure and declining sales, though cost-cutting initiatives and brand strength in segments like Rao's offer long-term potential. Key risks include execution of turnaround plans and competitive pressures. The consensus price target is $19.73, with most analysts rating Hold.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
